Addex Therapeutics to Attend H.C. Wainwright Investment Conference
![Addex Therapeutics to Attend H.C. Wainwright Investment Conference](https://investorshangout.com/images/blog/ihnews-Addex%20Therapeutics%20to%20Attend%20H.C.%20Wainwright%20Investment%20Conference.jpg)
Addex Therapeutics to Attend H.C. Wainwright Investment Conference
Geneva, Switzerland – Addex Therapeutics (SIX/NASDAQ: ADXN), a company dedicated to developing innovative small molecule allosteric modulators for neurological disorders, is excited to announce that its CEO, Tim Dyer, will attend the H.C. Wainwright 26th Annual Global Investment Conference. This event will occur at the Lotte New York Palace Hotel from September 9 to September 11, 2024.
Corporate Update Presentation
During the conference, a video presentation featuring Mr. Dyer will be available on-demand starting at 07:00 EDT on September 9, 2024. In this presentation, he will provide updates on Addex's corporate progress and discuss recent developments, reflecting the company’s commitment to advancing treatments for neurological conditions.
One-on-One Meetings
Tim Dyer will engage in one-on-one meetings throughout the event, offering stakeholders and interested parties the opportunity to have in-depth discussions about Addex's initiatives and advancements. For those seeking to schedule a meeting, please reach out to the company via the contact information provided below.
About Addex Therapeutics
As a clinical-stage biopharmaceutical company, Addex Therapeutics is at the forefront of developing a robust portfolio of allosteric modulators aimed at treating neurological disorders. The company’s leading drug candidate, dipraglurant, is specifically designed as a negative allosteric modulator targeted at the mGlu5 receptor, currently under evaluation for its potential in brain injury recovery, including recovery from strokes and traumatic brain injuries.
Collaborations and Future Developments
Addex has partnered with Indivior to progress a GABAB PAM drug candidate tailored for substance use disorders, with plans to initiate IND enabling studies in the first half of 2025. Additionally, Addex is independently advancing a GABAB PAM program aimed at addressing chronic cough and intends to start IND enabling studies in 2025.
Equity Interests and Other Projects
The company also holds a 20% stake in Neurosterix LLC, which is pursuing an exciting pipeline of allosteric modulator programs. These include development for schizophrenia with an M4 PAM, mood disorders involving an mGlu7 NAM, and mild neurocognitive disorders treated with an mGlu2 NAM. Addex's shares are publicly traded on both the SIX Swiss Exchange and the NASDAQ Capital Market under the ticker symbol ADXN.
Contact Information
Tim Dyer
Chief Executive Officer
Telephone: +41 22 884 15 55
Email: PR@addextherapeutics.com
Mike Sinclair
Partner, Halsin Partners
Telephone: +44 (0)20 7318 2955
Email: msinclair@halsin.com
Frequently Asked Questions
What is the H.C. Wainwright investment conference?
The H.C. Wainwright investment conference is an event where public companies present their business updates and opportunities to potential investors.
Who is the CEO of Addex Therapeutics?
Tim Dyer is the Chief Executive Officer of Addex Therapeutics.
What is Addex Therapeutics focused on?
Addex Therapeutics is focused on developing innovative small molecule allosteric modulators to treat various neurological disorders.
What are some of Addex's lead drug candidates?
Dipraglurant, aimed at brain injury recovery, is one of Addex's leading drug candidates.
How can I contact Addex Therapeutics?
You can contact Addex Therapeutics through their email PR@addextherapeutics.com for inquiries.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Related Articles
- General Silicones Expands Operations to Meet European Demand
- Australia's Stock Market Decline: Key Players and Insights
- Japan Stocks Decline as Nikkei 225 Faces 4.35% Drop
- Dwinity Revolutionizes Data Storage for Predictive AI
- Synthetic Dyes Market Expected to Reach $9.1 Billion by 2029
- Asian Tech Stocks: Insights Amid Market Volatility
- Taiwan Stock Market Update: Navigating Recent Declines
- Asian Markets React to Wall Street's August Decline
- BrilliantCrypto Unveils Mobile Game for Players Worldwide
- Morgan Stanley Invests in 3forge to Boost Capabilities
- Join Ignitis Group for Investor Day 2024: Exclusive Event
- Ignitis Group Hosts Exclusive Investor Day 2024 Event
- Roche's Fenebrutinib Achieves Major Milestone in MS Treatment
- NX Group's Strategic Investment in Japanese Drone Innovator Spiral
- Volvo Cars Set to Launch EX90 SUVs After Production Delay
- Cybersecurity Stocks Update: Fortinet, CrowdStrike, and Palo Alto
- Market Trends: Analysts Weigh In on Recent Stock Movements
- Nicox Welcomes Christine Placet to Board; Garufi Retires
- Telia Company Adjusts Operations to Enhance Profitability
- India's Services Sector Sees Strong Growth Amid Inflation Relief
- Market Turmoil: A Cautious Outlook for Investors Ahead
- China Shipyards Merge to Strengthen Maritime Capabilities
- Pharming Group Participates in Key Investor Conferences This Month
- Altair Partners with CBTW to Enhance Data Analytics in EMEA
- Thai King Supports New Cabinet Under PM Paetongtarn Shinawatra
Recent Articles
- Applied Materials Welcomes Florent Ducrot as European Leader
- MMDSmart Welcomes Methodios Chousmekiaris as CRO for Growth
- Axcellant Launches Innovative Clinical Trial in Nuclear Medicine
- Global Housing Market Expecting Modest Price Increases Ahead
- Ophthalmic Drugs Market Expected to Hit $67.83 Billion by 2033
- Investigation Into Mineralys Therapeutics, Inc. (MLYS) Claims
- Mexican Stock Market Experiences Significant Decline Today
- US Justice Department Probes Nvidia Antitrust Practices
- Brookfield Reveals New Dividend Rate for Series 40 Shares
- Nvidia Faces Antitrust Scrutiny from U.S. Justice Department
- Ascendis Pharma's Q2 2024 Financial Overview and Milestones
- Lifeway Foods to Showcase Growth at Annual Lake Street Conference
- Corporate Borrowers Tackle Bond Market Ahead of Fed Decision
- California Water Service Launches 2024 Firefighter Grants
- H&R Block to Engage at Barclays Global Financial Conference
- Phillips Edison & Company Boosts Monthly Dividends to $0.1025
- InVita Healthcare Technologies Enhances Organ Donation with iReferral
- Wealthtech Solutions Market Forecasted to Grow by $6.08 Billion
- Exploring the Potential for a 50bps Rate Cut by the Fed
- Al Hurra Cuts Jobs and Merges Iraq Channel Amid Budget Cuts
- Advancements in Cancer Detection Through Space Experiments
- Beeyou.tv Unveils New Features for Creators at IBC 2024 Event
- Silicon Valley Reacts to the Unrealized Gains Tax Proposal
- Invesco Closes End Funds Boost Dividend Rates for Investors
- 2024 FOCAC Summit: Strengthening China-Africa Cooperation